Rating Change
Wells Fargo reiterated its Equal-Weight rating on CRISPR Therapeutics AG (NASDAQ:CRSP) on November 04, 2026.
reiterateNASDAQ:CRSP
Wells Fargo Reiterates Equal-Weight Rating on CRISPR Therapeutics AG (CRSP)
Wells Fargo reiterated its Equal-Weight rating on CRISPR Therapeutics AG (NASDAQ:CRSP) on November 04, 2026.
At publication ·
What changed
CRISPR Therapeutics AG (NASDAQ:CRSP) · reiterate
- Firm
- Wells Fargo
- Rating
- Equal-Weight to Equal-Weight
- Price at event
- $51.78
- Market capitalization
- $5.1B
At a glance
Key takeaways
- Wells Fargo maintained an Equal-Weight rating on CRISPR Therapeutics, suggesting the stock is fairly valued at current levels around $51.77.
Market Context
CRISPR Therapeutics AG operates in the Healthcare sector. The stock currently trades at $51.77 with a market capitalization of $5.1B. The stock has declined 9.3% over the past 52 weeks.
Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for CRISPR Therapeutics AG.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for CRISPR Therapeutics AG
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 04, 2026 | Wells Fargo | Equal-Weight | N/A |
| Nov 03, 2026 | Needham | Buy | N/A |
| Oct 15, 2026 | UBS | Neutral | N/A |
| Aug 31, 2026 | Citizens | Market Outperform | N/A |
| Aug 31, 2026 | Needham | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CRSP Stock Page
Frequently Asked Questions
What does the Equal-Weight rating mean for CRSP?
A rating of Equal-Weight from Wells Fargo reflects the analyst's outlook on CRISPR Therapeutics AG (NASDAQ:CRSP). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CRSP forecast page.